Immune system factors including complement pathway activation are increasingly linked to the etiology and pathophysiology of schizophrenia. Complement protein, C1q, binds to and helps to clear immune complexes composed of immunoglobulins coupled to antigens. The antigenic stimuli for C1q activation in schizophrenia are not known. Food sensitivities characterized by elevated IgG antibodies to bovine milk caseins and wheat glutens have been reported in individuals with schizophrenia. Here, we examined the extent to which these food products might comprise the antigen component of complement C1q immune complexes in individuals with recent onset schizophrenia (n = 38), non-recent onset schizophrenia (n = 61) and non-psychiatric controls (n = 63). C1q seropositivity was significantly associated with both schizophrenia groups (recent onset, odds ratio (OR) = 8.02, p ≤ 0.008; non-recent onset, OR = 3.15, p ≤ 0.03) compared to controls (logistic regression models corrected for age, sex, race and smoking status). Casein-and/or gluten-IgG binding to C1q was significantly elevated in the non-recent onset group compared to controls (OR = 4.36, p ≤ 0.01). Significant amounts of C1q-casein/gluten-related immune complexes and C1q correlations with a marker for gastrointestinal inflammation in non-recent onset schizophrenia suggests a heightened rate of food antigens in the systemic circulation, perhaps via a disease-associated altered intestinal permeability. In individuals who are in the early stages of disease onset, C1q activation may reflect the formation of immune complexes with non-casein-or non-gluten-related antigens, the presence of C1q autoantibodies, and/or a dissociated state of immune complex components. In conclusion, complement activation may be a useful biomarker to diagnose schizophrenia early during the course of the disease. Future prospective studies should evaluate the impacts of casein-and gluten-free diets on C1q activation in schizophrenia.
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Introduction
Immune system factors are becoming increasingly linked to the etiology and pathophysiology of complex neurodevelopmental brain diseases such as schizophrenia and autism (Abazyan et al., 2010; Brown, 2011; Brown and Patterson, 2011; Dohan, 1981; Onore et al., 2011; Reichelt and Landmark, 1995; Rossignol and Frye, 2011; Shi et al., 2009; Stefansson et al., 2009; Yolken and Torrey, 2008) .
We have reported strong associations between schizophrenia and a variety of infectious disease and food-derived antigens (Dickerson et al., 2010a (Dickerson et al., , 2010b Leweke et al., 2004; Niebuhr et al., 2008; Severance et al., 2010a Severance et al., , 2011a Severance et al., , 2012 Yolken and Torrey, 2008) . If antigenic exposures play a part in the pathogenesis of schizophrenia, we might expect that immune components involved in early stages of antigen clearance are also affected.
The classic complement pathway immune mediator, C1q, is of particular relevance in this regard and to studies of brain disorders, because it functions both in antigen elimination and in synapse development (Boulanger, 2009; Stevens et al., 2007; Walport, 2001a Walport, , 2001b . C1q is best known for its role in binding to and facilitating the clearing of antigen-antibody immune complexes from systemic circulation (Walport, 2001a (Walport, , 2001b 
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